Use Of Preferred Providers Among Large Molecule Outsourcers
Source: ISR Reports
In Q32021, ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced biologic manufacturing. The data show use of preferred providers is equally likely among biologic API manufacturing as it is for biologic product manufacturing. To learn more, follow the links to the Biologic API and the Biologic Drug Product report previews.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more